Mersana Therapeutics Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Marty Huber
Chief Executive Officer (CEO)
US$3.0m
Compensación total
| Porcentaje del salario del CEO | 6.4% |
| Permanencia del CEO | less than a year |
| Participación del CEO | n/a |
| Permanencia media de la dirección | 3.3yrs |
| Promedio de permanencia en la Junta Directiva | 7.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%
Apr 25
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry
Feb 27Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock
Jan 11Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money
Oct 14Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Jun 09Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price
Feb 22Mersana gains as FDA grants fast track status for breast cancer drug
Sep 12Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed
Aug 15Taking The Measure Of Mersana Therapeutics
Jan 10Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress
Jun 29It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year
Jun 05Mersana Therapeutics EPS misses by $0.11, misses on revenue
May 10Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Mar 23Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?
Jan 29
Bain Capital discloses 4.8% stake in Mersana Therapeutics
Jan 13Mersana: XMT-1536's Complications, New CMO, And 2H 2021's Critical Catalyst
Jan 11Mersana slumps as XMT-1536 shows lower response rate in ovarian cancer study
Jan 05Is Mersana Therapeutics, Inc. (NASDAQ:MRSN) Trading At A 42% Discount?
Dec 08Mersana Therapeutics EPS misses by $0.02
Nov 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$194k | -US$172m |
| Sep 30 2023 | n/a | n/a | -US$197m |
| Jun 30 2023 | n/a | n/a | -US$215m |
| Mar 31 2023 | n/a | n/a | -US$213m |
| Dec 31 2022 | US$163k | n/a | -US$204m |
| Sep 30 2022 | n/a | n/a | -US$208m |
| Jun 30 2022 | n/a | n/a | -US$194m |
| Mar 31 2022 | n/a | n/a | -US$183m |
| Dec 31 2021 | US$290k | n/a | -US$170m |
| Sep 30 2021 | n/a | n/a | -US$150m |
| Jun 30 2021 | n/a | n/a | -US$127m |
| Mar 31 2021 | n/a | n/a | -US$106m |
| Dec 31 2020 | US$303k | n/a | -US$88m |
Compensación vs. Mercado: La compensación total ($USD3.04M) de Marty está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.37M).
Compensación vs. Ingresos: La compensación de Marty ha aumentado mientras la empresa no es rentable.
CEO
Marty Huber (62 yo)
less than a year
Permanencia
US$3,044,085
Compensación
Dr. Martin H. Huber, also known as Marty, M.D., is President and Chief Executive Officer at Mersana Therapeutics, Inc. since September 2023. He served as President and Head of R&D at Xilio Therapeutics, In...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | less than a year | US$3.04m | sin datos | |
| Senior VP | 4.8yrs | US$1.74m | 0.045% $ 161.7k | |
| Senior VP and Chief Science & Technology Officer | 16.2yrs | US$1.69m | 0.16% $ 591.1k | |
| Senior VP | 3yrs | US$1.61m | 0.023% $ 81.3k | |
| Senior VP & Chief Development Officer | 2.5yrs | US$1.58m | 0.012% $ 41.7k | |
| Co-Founder | no data | sin datos | sin datos | |
| Chief Accounting Officer | 4.6yrs | sin datos | 0.021% $ 77.0k | |
| Senior Vice President of Investor Relations & Corporate Communications | no data | sin datos | sin datos | |
| Senior Vice President of Regulatory Affairs | 3.7yrs | sin datos | sin datos | |
| Exe. Director and Head of Biology | no data | sin datos | sin datos | |
| Senior VP & Chief Manufacturing Officer | 2.7yrs | US$1.68m | 0.015% $ 53.3k |
3.3yrs
Permanencia media
58yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de MRSN se considera experimentado (3.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4yrs | US$3.04m | sin datos | |
| Independent Chairman | 11.8yrs | US$329.93k | 0.48% $ 1.7m | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 6.6yrs | US$308.93k | 0.0018% $ 6.3k | |
| Independent Director | 6.1yrs | US$305.43k | 0.020% $ 73.3k | |
| Independent Director | 7.7yrs | US$293.43k | 0% $ 0 | |
| Director | 9.1yrs | US$4.65m | 0.35% $ 1.2m | |
| Independent Director | 7.3yrs | US$297.43k | 0% $ 0 | |
| Board Observer | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
7.3yrs
Permanencia media
59.5yo
Promedio de edad
Junta con experiencia: La junta directiva de MRSN se considera experimentada (7.3 años de antigüedad promedio).